Chondrosarcoma- Pipeline Insight, 2025

This “Chondrosarcoma- Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Chondrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Chondrosarcoma: Understanding

Chondrosarcoma: Overview

Chondrosarcoma is a rare type of cancer that originates in the cartilage cells. It is the second most common primary malignancy of bone, typically affecting adults aged 40-70. Unlike other bone cancers, chondrosarcoma is slow-growing but can vary significantly in aggressiveness depending on the subtype. It most often occurs in the pelvis, ribs, and long bones like the femur and humerus. Subtypes include conventional, clear cell, dedifferentiated, and mesenchymal chondrosarcoma, each with distinct characteristics and behaviors.

Patients with chondrosarcoma often present with a dull, persistent pain in the affected area, which may worsen over time. Other symptoms include localized swelling or a palpable mass, restricted joint movement, or nerve compression if the tumor presses against nearby structures. In more aggressive forms, systemic symptoms like weight loss and fatigue may appear. Depending on the tumor's location, it can also lead to fractures or functional impairments.

The exact cause of chondrosarcoma remains unclear, but several risk factors have been identified. It can arise de novo or develop from preexisting benign cartilage tumors like enchondromas or osteochondromas. Genetic conditions, such as Ollier disease and Maffucci syndrome, increase the risk. Mutations in genes like IDH1, IDH2, and COL2A1 are commonly associated with the disease. Environmental factors, such as radiation exposure, may also play a role in rare cases.

Diagnosing chondrosarcoma begins with a thorough clinical evaluation and imaging studies. X-rays typically reveal a lytic lesion with calcifications, while MRI helps assess the tumor’s size, extent, and relationship to surrounding tissues. A CT scan is useful for evaluating mineralization and cortical bone involvement. Definitive diagnosis requires a biopsy, where a tissue sample is analyzed for histological grading. Higher-grade tumors have greater cellular atypia, mitotic activity, and necrosis, correlating with worse prognosis.

The primary treatment for chondrosarcoma is surgical resection with wide margins to minimize recurrence. The type of surgery depends on the tumor's size, grade, and location. Low-grade tumors may require curettage or intralesional excision, while high-grade or aggressive tumors necessitate extensive procedures, potentially including amputation. Chemotherapy and radiation are typically ineffective for conventional chondrosarcomas but may benefit certain subtypes like mesenchymal or dedifferentiated forms. Targeted therapies based on molecular alterations are being explored in clinical trials.

"Chondrosarcoma- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.

Chondrosarcoma Emerging Drugs Chapters

This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chondrosarcoma Emerging Drugs

Trabectedin: PharmaMar

Trabectedin, also known as ecteinascidin 743 or ET-743l, or commercially where it is approved as Yondelis is a synthetic compound derived from the colonial sea squirt Ecteinascidia turbinata. Trabectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

Trabectedin (Yondelis) is an anti-tumor agent of marine origin discovered in the caribbean tunicate, ecteinascidia turbinata. It is formulated as lyophilized powder for solution for injection for intravenous route of administration. Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Mesenchymal Chondrosarcoma.

Seclidemstat: Salarius Pharmaceuticals, LLC

Seclidemstat (SP-2577) is a differentiated inhibitor of LSD1, which is a well-validated target for both hematological and solid tumors. SP-2577 inhibits LSD1’s enzymatic activity and its scaffolding function. In early 2021, Salarius completed the dose escalation portion of the trial, demonstrating that SP-2577 can be given at doses that are tolerable, provide adequate drug exposure, and show preliminary signs of activity. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Extraskeletal Myxoid Chondrosarcoma.

• Ifosfamide: Atlanthera

Ifosfamide, is an investigational drug being developed by Atlanthera. The drug acts as a DNA synthesis inhibitor. Currently the drug is in Preclinical stage of development for the treatment of Chondrosarcoma.

Chondrosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chondrosarcoma

There are approx. 12+ key companies which are developing the therapies for Chondrosarcoma. The companies which have their Chondrosarcoma drug candidates in the most advanced stage, i.e. Phase II include, PharmaMar.

Phases

The report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chondrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chondrosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.

Chondrosarcoma Report Insights

• Chondrosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chondrosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chondrosarcoma drugs?
• How many Chondrosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chondrosarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chondrosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• PharmaMar
• Salarius Pharmaceuticals, LLC
• Atlanthera
• Iovance Biotherapeutics
• Ipsen

Key Products

• Trabectedin
• Seclidemstat
• Ifosfamide
• LN-145
• Tazemetostat

This product will be delivered within 2 business days.